Novartis’s Latest Trial Setback Sinks Stock

Investors felt the sting of a sudden 9% slide in Novartis shares, a sharp reversal after weeks of optimism that the Avidity acquisition would boost the pipeline. The surprise is that a drug acquired for its promise has now faltered twice within a single week, turning what looked like a strategic win into a market disappointment that rattled shareholders and analysts alike. Bloomberg reported the third setback in a week, noting the Phase III HARBOR study of delpacibart etedesiran missed its primary endpoints, ending hopes for a treatment of myotonic dystrophy type 1.

The Wall Street Journal framed the episode as a cautionary tale for pharmaceutical mergers and acquisitions, warning that aggressive deal‑making may not guarantee clinical success. CNBC focused on the immediate market reaction, citing a 9% drop in the share price and heightened volatility. The Phase III HARBOR trial, designed to treat myotonic dystrophy type 1, failed to meet its primary goals, echoing an earlier disappointment in the same molecule reported earlier in the week.

The twin setbacks have left the pipeline outlook uncertain, prompting analysts to monitor whether Novartis will redesign the program, seek regulatory relief, or allocate resources to alternative candidates. The open question now is how the company will address the pipeline gap and restore investor confidence amid strained M&A expectations.